Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03843515
Other study ID # 2018-002643
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date April 11, 2019
Est. completion date August 31, 2022

Study information

Verified date October 2021
Source VU University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction


Description:

Intensive treatment regimens with surgical resection and adjuvant (chemo)radiotherapy of patients with locally advanced oral cancer still result in only 50-60% cure rate, leaving a substantial group of patients who will develop a local recurrence or distant metastases with minimal curative salvage treatment options. Treatment with anti-PD-1 monoclonal antibodies (mAbs) has shown promise in patients with recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). This supports the hypothesis that including treatment with anti PD-1 mAb nivolumab could improve the outcome for patients with locally advanced oral cancer resulting in a higher cure rate. Response rate with nivolumab was below 20% in unselected patients with r/m HNSCC. Therefore, biomarkers for response are urgently needed. Tumor PD-L1 immunohistochemistry (IHC) was shown to be related to nivolumab response but cannot be reliably used for patient selection. Temporal and spatial heterogeneity of tumor PD-L1 expression (within and between tumor lesions) might be responsible for its suboptimal predictive value as biomarker of response. Therefore there is a need to further evaluate tumor PD-L1 expression as predictive biomarker, as well as exploring alternatives. Serial PET imaging with [18F]BMS-986192 (anti-PD-L1 tracer) and [18F]-FDG has the potential to provide whole body information of the patient over time, at baseline as well as on treatment and represents a biomarker for toxicity and efficacy. In addition, we will investigate the immunophenotype of the patient and tumor, as well as the presence of neoantigens and other potential other biomarkers such as plasma vesicle miRNAs.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 17
Est. completion date August 31, 2022
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Have a histologically confirmed diagnosis of locally advanced oral cancer (stage III/IV) which is planned for treatment with curative intent including surgical resection. 2. Be willing and able to provide written informed consent/assent for the trial. 3. Be more then 18 years of age on day of signing informed consent. 4. Must agree to provide tissue from fresh tumor biopsy pretreatment and from the surgical resection material to determine the actual PD-L1 status and perform immunomonitoring/DNA/RNA profiling. 5. Willing to allow up to two additional biopsies when baseline [18F]BMS-986192 PET /[18F]-FDG PET scans show heterogeneous and/or discrepant uptake. 6. Have a performance status of 0-1 on the ECOG Performance Scale (Appendix 2). 7. Demonstrate adequate organ function as defined in table 1. All screening labs should be performed within 2 weeks before any study imaging procedures are performed 8. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception during the study and for 23 weeks after the last dose of nivolumab. Women who are not of childbearing potential (i.e. who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception (Appendix 4) 9. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception during the study and for 31 weeks after the last dose of nivolumab (Appendix 4). Exclusion Criteria: 1. Is currently participating in or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment or has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 2. Has had another known invasive malignancy within the previous 5 years and/or has had surgery, chemotherapy, targeted small molecule therapy or radiation therapy within 5 years for a known malignancy prior to study day 0. 3. Has a known current additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. 4. If subject received major surgery for any other reason, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. 5. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day -5. Inhaled or topical steroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. 6. Has an active autoimmune disease requiring systemic steroid treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids. 7. Has evidence of interstitial lung disease or active, non-infectious pneumonitis. 8. Has an active infection requiring systemic therapy. 9. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 10. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 11. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 23 weeks after the last dose of trial treatment. 12. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways. 13. Has a known history of Human Immunodeficiency Virus (HIV) infection (HIV 1/2 antibodies). 14. Has known active Hepatitis B or C.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nivolumab
Neoadjuvant nivolumab flat dose 400mg

Locations

Country Name City State
Netherlands VU University medical center Amsterdam Noord-Holland

Sponsors (2)

Lead Sponsor Collaborator
VU University Medical Center Bristol-Myers Squibb

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary (Serious) adverse events Adverse events untill 100 days after last study drug administration
Primary SUV values SUVpeak/mean/max of tumor lesions on FDG-PET/anti-PD-L1 PET 2 years
Secondary Correlation between PET data and Blood/Tissue markers The correlation between continuous values as SUV and the categorical variables tissue PD-1 and PD-L1 IHC will be assessed for each tumor lesion. Correlation with immuno-monitoring analysis in tumor tissue/lymph nodes and blood, plasma vesicle miRNAs from blood, as well as DNA/RNA profiling in tumor tissue at baseline and at surgery will be assessed. 2 years
See also
  Status Clinical Trial Phase
Completed NCT03650699 - Biofeedback Rehabilitation to Improve Speaking and Eating in Public N/A
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Terminated NCT03053960 - Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
Recruiting NCT05876247 - Articulatory Adaptation Following Oral Cancer Treatment
Completed NCT03618654 - Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Early Phase 1
Recruiting NCT04801472 - Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) N/A
Recruiting NCT04858269 - First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Phase 2
Active, not recruiting NCT03529604 - Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
Completed NCT03028766 - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer Phase 1
Recruiting NCT05681039 - Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). Phase 2
Completed NCT03510390 - Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation N/A
Recruiting NCT05578170 - Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma
Recruiting NCT05950737 - Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience N/A
Recruiting NCT04333537 - Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer Phase 2/Phase 3
Recruiting NCT03727594 - Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
Terminated NCT02582008 - Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Early Phase 1
Recruiting NCT05749042 - A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma Phase 2
Recruiting NCT06097468 - Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) Phase 1/Phase 2
Withdrawn NCT04892875 - A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Phase 1
Active, not recruiting NCT03784066 - Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity Phase 1/Phase 2